← All Relay Therapeutics, INC filings

Relay Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RLAY
Relay Therapeutics, INC
10-K: Relay Therapeutics Advances Zovegalisib with FDA Breakthrough Status
Relay Therapeutics' 2025 annual report highlights significant clinical progress for its lead candidate zovegalisib, including FDA Breakthrough Therapy designation, alongside strategic financial adjustments.
NASDAQ
RLAY
Relay Therapeutics, INC
10-K: Relay Therapeutics Reports 2024 Results, Highlights RLY-2608 Progress and Pipeline Expansion
Relay Therapeutics' 10-K filing summarizes the company's financial results for 2024, highlights the clinical progress of RLY-2608, and outlines its strategy for pipeline expansion in precision oncology and genetic diseases.
NASDAQ
RLAY
Relay Therapeutics, INC
10-K: Relay Therapeutics Outlines Securities and Corporate Governance in 10-K Filing
Relay Therapeutics' 10-K filing details the company's capital structure, registration rights, anti-takeover provisions, and other corporate governance matters.